Steatel, solution for injection, 1g/5ml, 5 ampoules — Made in Greece — Free Delivery

Steatel solution for injection is used for the treatment of primary and secondary carnitine deficiency in adults and children, including newborns and infants. Secondary carnitine deficiency in patients undergoing hemodialysis.

Suspected secondary carnitine deficiency in patients undergoing hemodialysis in the following cases:

Active substance: levocarnitine;

1 ml 200 mg levocarnitine;

Excipients: diluted hydrochloric acid, water for injection.

Hypersensitivity to the components of the preparation.

The preparation is administered intravenously slowly over 2-3 minutes.

Application for congenital metabolic disorders. During therapy, it is advisable to control the level of carnitine and acylcarnitine in both blood plasma and urine. The required dose depends on the specificity of the congenital metabolic disorder and the severity of the manifestations of the disease. In the case of acute decompensation, the recommended dose may be up to 100 mg / kg per day in 3-4 injections. Higher doses can be used if necessary, although side effects such as diarrhea may increase.

Pregnant

Given the serious consequences of carnitine deficiency for a pregnant woman, the risk of interruption to treatment for the mother is considered greater than the theoretical risk to the fetus if treatment is continued.

Children

The preparation is used in children from the first day of life, including premature babies.

There have been no reports of overdose toxicity of levocarnitine. To treat an overdose, supportive therapy should be given. Large doses can cause diarrhea. Levocarnitine is easily removed from blood plasma by dialysis. Treatment: take measures to remove the preparation from the digestive tract when ingested, conduct symptomatic and supportive therapy. No cases of overdose that were life-threatening were reported.

Moderate gastrointestinal distress has been observed with long-term use of oral levocarnitine, including fleeting nausea and vomiting, abdominal pain, and diarrhea. Reducing the dose often reduces or eliminates gastrointestinal symptoms. With long-term administration of oral levocarnitine, it is necessary to control the specific body odor (reducing the dose weakens or eliminates the odor caused by the preparation). When taking levocarnitine with coumarin anticoagulants, an increase in the international normative ratio of INR is possible. It is necessary to carefully monitor the tolerance of the preparation during the first week of administration and after any dose increase. Intravenous administration of levocarnitine is generally well tolerated.

The simultaneous use of glucocorticoids leads to the accumulation of levocarnitine in body tissues (except for the liver). Other anabolic agents enhance the effect of the preparation.

In some cases, when taking levocarnitine with coumarin anticoagulants, an increase in the international normative ratio of INR is possible, therefore, their simultaneous use requires a reservation. INR or other coagulation tests should be checked weekly until they stabilize, and monthly thereafter in patients taking such anticoagulants with levocarnitine.

Store at a temperature not exceeding 25 ° C in a dark place.

Keep out of the reach of children.

Shelf life is 3 years.